Based on the ongoing activities in the ARD-101 program, Aardvark no longer anticipates announcing topline data from the HERO trial in the third quarter of 2026 and expects to provide further guidance ...
Add Yahoo as a preferred source to see more of our stories on Google. An aardvark in the Tussen-die-Riviere Nature Reserve in South Africa. Nigel Denis / Alamy via bioGraphic Animals of all kinds mix ...
Ants stick to their tongue, like flies stick to fly paper, but the adaptations don’t stop there. Once swallowed and shunted further along the digestive system, the food arrives in a gizzard-like ...
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...
These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the treatment of hyperphagia associated with Prader-Willi ...
Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients who have completed HERO trial to date have successfully enrolled and remain in the Open ...
Aardvark Therapeutics, Inc. announced key leadership appointments to enhance its team as it progresses with its Phase 3 HERO study of ARD-101 for treating hyperphagia associated with Prader-Willi ...
Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results